Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry  Yan.

Slides:



Advertisements
Similar presentations
Lung Adenocarcinoma with Ipsilateral Breast Metastasis: A Simple Coincidence? Hsu-Ching Huang, MD, Jen-Fan Hang, MD, Mei-Han Wu, MD, Teh-Ying Chou, MD,
Advertisements

Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.
A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab  Monica Khunger, MD  Journal of Thoracic.
A 51-Year-Old Woman With an Increasing Chest Wall Mass Years After Resection of an Early Stage Lung Cancer  Ajay Dhakal, MBBS, Hongbin Chen, MD, PhD,
Next Generation Sequencing Uncovers Potential Genetic Driver Mutations of Malignant Pulmonary Granular Cell Tumor  Song Xu, Qingchun Zhao, Sen Wei, Yi.
Secondary Mutations at I1171 in the ALK Gene Confer Resistance to Both Crizotinib and Alectinib  Gouji Toyokawa, MD, PhD, Fumihiko Hirai, MD, PhD, Eiko.
PET/CT Fusion Scan in Lung Cancer: Current Recommendations and Innovations  Cristina Gámez, MD, PhD, Rafael Rosell, MD, PhD, Alejandro Fernández, MD, PhD,
Hironori Yoshida, MD, Young Hak Kim, MD  Journal of Thoracic Oncology 
Response to Crizotinib/Erlotinib Combination in a Patient with a Primary EGFR-Mutant Adenocarcinoma and a Primary c-met–Amplified Adenocarcinoma of the.
ALK FISH and IHC: You Cannot Have One without the Other
Response to Osimertinib in Choroidal Metastases from EGFRmt T790M–Positive Non– Small Cell Lung Adenocarcinoma  Filippo Gustavo Dall’Olio, MD, Celeste.
Response to Crizotinib Rechallenge after Initial Progression and Intervening Chemotherapy in ALK Lung Cancer  Eiko Theodora Browning, MD, Andrew James.
A Sensitive ALK Immunohistochemistry Companion Diagnostic Test Identifies Patients Eligible for Treatment with Crizotinib  Trish Thorne-Nuzzo, BS, Crystal.
ALK Status Testing in Non–Small Cell Lung Carcinoma
MET-Mutated NSCLC with Major Response to Crizotinib
A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab  Monica Khunger, MD  Journal of Thoracic.
Victoria Wang, MD, PhD, Trever Bivona, MD, PhD 
Electronic Updates for JTO Readers
Rapid Response of Brain Metastasis to Crizotinib in a Patient with ALK Rearrangement– Positive Non–Small-Cell Lung Cancer  Hiroyasu Kaneda, MD, PhD, Isamu.
Interpretation of Anti-ALK Immunohistochemistry Results
High-Dose Crizotinib for Brain Metastases Refractory to Standard-Dose Crizotinib  Young Hak Kim, MD, Hiroaki Ozasa, MD, Hiroki Nagai, MD, Yuichi Sakamori,
Complete Response Achieved 1 Year after a Single Administration of Nivolumab in a Patient with Lung Adenocarcinoma with Negative Expression of PD-L1 
A Case of Lung Adenocarcinoma Resistant to Crizotinib Harboring a Novel EML4-ALK Variant, Exon 6 of EML4 Fused to Exon 18 of ALK  Satoshi Anai, MD, Masafumi.
Successful Crizotinib Retreatment after Crizotinib-Induced Interstitial Lung Disease  Satoru Yanagisawa, MD, PhD, Akira Inoue, MD, PhD, Akira Koarai, MD,
Hironori Yoshida, MD, Young Hak Kim, MD  Journal of Thoracic Oncology 
Esophageal Ultrasound-Controlled Fine Needle Aspiration for Staging of Mediastinal Lymph Nodes in Patients with Resectable Lung Cancer: Do We Always See.
A Severe Photosensitivity Dermatitis Caused by Crizotinib
The Central Nervous System as a Sanctuary Site in ALK-Positive Non–Small-Cell Lung Cancer  Justin F. Gainor, MD, Sai-Hong Ignatius Ou, MD, PhD, Jennifer.
A Case of Invasive Mucinous Pulmonary Adenocarcinoma with a CD74-NRG1 Fusion Protein Targeted with Afatinib  Parneet K. Cheema, MD, MBiotech, FRCPC  Journal.
A Sensitive ALK Immunohistochemistry Companion Diagnostic Test Identifies Patients Eligible for Treatment with Crizotinib  Trish Thorne-Nuzzo, BS, Crystal.
A Novel EML4-ALK Variant: Exon 6 of EML4 Fused to Exon 19 of ALK
Evaluating Cryoablation of Metastatic Lung Tumors in Patients—Safety and Efficacy The ECLIPSE Trial—Interim Analysis at 1 Year  Thierry de Baere, MD,
Jeffrey Bradley, MD, Issam El Naqa, PhD  Journal of Thoracic Oncology 
Crizotinib Improves Osteoarthritis Symptoms in a ROS1-Fusion Advanced Non–Small Cell Lung Cancer Patient  Jordi Remon, MD, Anas Gazzah, MD, Benjamin Besse,
Disease Flare After Treatment Discontinuation in a Patient With EML4-ALK Lung Cancer and Acquired Resistance to Crizotinib  Oana Pop, MD, Augustin Pirvu,
Transformation to SCLC after Treatment with the ALK Inhibitor Alectinib  Shiro Fujita, MD, PhD, Katsuhiro Masago, MD, PhD, Nobuyuki Katakami, MD, PhD,
Jeffrey T. Yorio, MD, Yang Xie, PhD, Jingsheng Yan, PhD, David E
Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q
Elderly Former Smoker with HRAS Mutant Non–Small-Cell Lung Cancer
Ineffectiveness of Crizotinib on Brain Metastases in Two Cases of Lung Adenocarcinoma with EML4-ALK Rearrangement  Denis Maillet, MD, Isabelle Martel-Lafay,
A Different Method in Diagnosis of Multiple Primary Lung Cancer
Nivolumab-Induced Acute Diabetes Mellitus and Hypophysitis in a Patient with Advanced Pulmonary Pleomorphic Carcinoma with a Prolonged Tumor Response 
Four-Year Complete Remission in a Patient with Metastatic Epidermal Growth Factor Receptor–Mutated Lung Cancer Treated with Two Cycles of Erlotinib  Brendan.
Arnaud Uguen, MD, PhD  Journal of Thoracic Oncology 
A Case of ALK-Rearranged Adenocarcinoma with Small Cell Carcinoma-Like Transformation and Resistance to Crizotinib  Yoon Jin Cha, MD, PhD, Byoung Chul.
High MET Receptor Expression But Not Gene Amplification in ALK 2p23 Rearrangement Positive Non–Small-Cell Lung Cancer  Yan Feng, MD, Eugen C. Minca, MD,
Osteoblastic Bone Lesions Developing During Treatment with Erlotinib Indicate Major Response in Patients with Non-small Cell Lung Cancer: A Brief Report 
ALK Translocation in Non-small Cell Lung Cancer with Adenocarcinoma and Squamous Cell Carcinoma Markers  Samuel J. Klempner, MD, David W. Cohen, MD, Daniel.
Osimertinib for Epidermal Growth Factor Receptor Mutation–Positive Lung Adenocarcinoma That Transformed to T790M-Positive Squamous Cell Carcinoma  Naoyuki.
Mirror Mirror on the Wall, Who Is the Fairest of Them All
EGFR delE709_T710insD: A Rare but Potentially EGFR Inhibitor Responsive Mutation in Non–Small-Cell Lung Cancer  Allison Ackerman, MD, Michael A. Goldstein,
S768I Mutation in EGFR in Patients with Lung Cancer
Atypical Negative ALK Break-Apart FISH Harboring a Crizotinib-Responsive ALK Rearrangement in Non–Small-Cell Lung Cancer  Shengxiang Ren, MD, PhD, Fred.
Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies  Mary Linton B Peters, MD,
T4 or MI? Journal of Thoracic Oncology Volume 6, Issue 3, (March 2011)
Two Generations of Light/Never-Smokers With Advanced Adenocarcinoma of the Lung with Durable Responses to Erlotinib  Nathan A. Pennell, MD, PhD, Lihong.
Jie Huang, Juan Peng, Linlang Guo, MD, PhD 
Antiangiogenesis Induced Tumor Cavitation in Lung Cancer
Concomitant Epidermal Growth Factor Receptor Mutation and EML4-ALK Fusion in a Patient with Multifocal Lung Adenocarcinomas  Jun Fan, MD  Journal of Thoracic.
Andreas Rimner, MD, Kenneth E. Rosenzweig, MD 
Impressive Response to Tyrosine Kinase Inhibitors in a Patient with Respiratory Failure for EGFR-Mutated Metastatic Lung Cancer  Elena Bolzacchini, MD,
Metastatic Lung Cancer to the Pancreas
Intrathoracic Desmoid Tumor: Brief Report and Review of Literature
Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping  Wei Jin, MD, Benjie Shan, MD, Hu Liu, PhD, Shoubing Zhou, PhD, Wenjuan.
Todd J. Carpenter, MD, Kenneth E. Rosenzweig, MD 
Tumor Lysis Syndrome in Limited-Stage Small-Cell Lung Cancer
David Garfield, MD  Journal of Thoracic Oncology 
Adding Bevacizumab to Chemotherapy Effectively Control Radioresistant Brain Metastases in ALK-Positive Lung Adenocarcinoma  Yu-Li Su, MD  Journal of Thoracic.
A Dramatic Response to Crizotinib in a Non–Small-Cell Lung Cancer Patient with IHC- Positive and FISH-Negative ALK  Jong-Mu Sun, MD, PhD, Yoon-La Choi,
ALK Status Testing in Non–Small-Cell Lung Carcinoma by FISH on ThinPrep Slides with Cytology Material  Eugen C. Minca, MD, PhD, Christopher P. Lanigan,
Presentation transcript:

Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry  Yan Feng, MD, PhD, Arun D. Singh, MD, Christopher Lanigan, MS, Raymond R. Tubbs, DO, Patrick C. Ma, MD  Journal of Thoracic Oncology  Volume 8, Issue 12, Pages e109-e111 (December 2013) DOI: 10.1097/01.JTO.0000437502.82078.9b Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Retinal images and ocular ultrasonography of patient’s left (L) and right (R) eye at diagnosis (1A, top) and after 10 months of crizotinib therapy (1B, bottom). Journal of Thoracic Oncology 2013 8, e109-e111DOI: (10.1097/01.JTO.0000437502.82078.9b) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 PET/CT scans indicating patient’s left lower lobe mass and left hilar adenopathy at diagnosis (2A), progression after 5 months of erlotinib (2B) and complete response after 14 months of crizotinib (2C). Journal of Thoracic Oncology 2013 8, e109-e111DOI: (10.1097/01.JTO.0000437502.82078.9b) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3 ALK immunohistochemistry (IHC) expression analysis on patient’s tumor (left: 4X, right: 20X). Journal of Thoracic Oncology 2013 8, e109-e111DOI: (10.1097/01.JTO.0000437502.82078.9b) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.